Jump Financial LLC Grows Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Jump Financial LLC grew its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 80.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 173,890 shares of the company’s stock after purchasing an additional 77,699 shares during the period. Jump Financial LLC owned approximately 0.20% of Syndax Pharmaceuticals worth $2,299,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals in the fourth quarter valued at about $26,000. Cape Investment Advisory Inc. boosted its stake in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after purchasing an additional 3,927 shares in the last quarter. KBC Group NV grew its position in Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after purchasing an additional 3,559 shares during the last quarter. Optimize Financial Inc acquired a new position in Syndax Pharmaceuticals during the 4th quarter valued at approximately $152,000. Finally, Guggenheim Capital LLC acquired a new position in Syndax Pharmaceuticals during the 4th quarter valued at approximately $157,000.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. This represents a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock valued at $336,087 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Scotiabank dropped their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th. JPMorgan Chase & Co. lifted their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 20th. Citigroup dropped their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $36.20.

Syndax Pharmaceuticals Stock Up 4.1 %

NASDAQ:SNDX opened at $11.51 on Friday. The stock has a market capitalization of $989.94 million, a PE ratio of -3.17 and a beta of 1.28. Syndax Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $25.07. The stock’s 50-day moving average price is $13.27 and its 200-day moving average price is $15.09.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. Sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).